Planet 13 Announces Record Third Quarter 2020 Financial Results

  • Q3 2020 Revenue of $22.8 million; Adjusted EBITDA of $6.2 million

All figures are reported in United States dollars ($) unless otherwise indicated

LAS VEGAS, NV / ACCESSWIRE / November 24, 2020 / Planet 13 Holdings Inc. (CSE:PLTH) (OTCQB:PLNHF) ("Planet 13" or the "Company"), a leading vertically-integrated Nevada cannabis company, today announced its financial results for the three-month and nine-month period ended September 30, 2020. Planet 13's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

Larry Scheffler, Co-CEO of Planet 13 said, "Our performance in the third quarter exceeded expectations - leading to our highest quarter of sales ever. Despite being impacted by the ongoing global pandemic and our Las Vegas SuperStore only at 50% capacity, we achieved 36% higher revenue compared to pre-COVID quarters. This is a testament to the strength of Planet 13's business model and the success of the operational improvements we put in place to ensure our ability to serve local customers. As Las Vegas returns to normal and the economy recovers, we will undertake further strategic initiatives to grow revenue at the SuperStore and increase our sales to local customers in Las Vegas."

"In the third quarter, our in-house brands contributed 25% to SuperStore revenue - continuing to be one of the most recognized and fastest-growing segments within the Planet 13 portfolio. In the wholesale market we saw increasing sales month over month throughout the quarter and continuing into October. Building on this momentum, we continue to invest in cultivation with our recently announced acquisition of a 45,000 square foot facility in Las Vegas, better positioning us to supply wholesale and retail sales within the state," commented Bob Groesbeck, Co-CEO. "We are excited to leverage our knowledge and experience from Nevada to California, with the opening of our new dispensary in Santa Ana in 2021 - the world's second largest dispensary. Planet 13 is well capitalized, and we look forward to executing on future expansion into other major growth markets."

Financial Highlights - Q3 - 2020

Operating Results

All comparisons below are to the quarter ended September 30, 2019, unless otherwise noted

  • Revenues were $22.8 million as compared to $16.7 million, an increase of 36.5%

  • Gross profit before biological adjustments was $13.0 million or 56.9% as compared to $9.9 million or 59.1%, an increase of 31.4%

  • Operating expenses, excluding non-cash compensation expense and depreciation and amortization, was $7.2 million as compared to $6.7 million, an increase of 7.9%

  • Net income before taxes of $3.4 million as compared to a net income of $0.3 million

  • Net income of $0.2 million as compared to a net loss of $1.7 million

  • Adjusted EBITDA of $6.2 million as compared to Adjusted EBITDA of $3.4 million

Balance Sheet

All comparisons below are to December 31, 2019, unless otherwise noted

  • Cash of $56.8 million as compared to $12.8 million

  • Total assets of $125.5 million as compared to $62.9 million

  • Total liabilities of $39.3 million as compared to $21.6 million

Q3 Highlights and Recent Developments

For a more comprehensive overview of these highlights and recent developments, please refer to Planet 13's Management's Discussion and Analysis of the Financial Condition and Results of Operations for the Three Months and Nine Months Ended September 30, 2020 (the "MD&A").

  • On July 3, 2020, Planet 13 announced closing of a CDN$11.5 million bought deal public offering.

  • On July 17, 2020, Planet 13 announced an acquisition of 45,000 square feet of indoor cultivation.

  • On August 10, 2020, Planet 13 was awarded a Nevada dispensary license.

  • On August 20, 2020, Planet 13 announced a CDN$15 million bought deal public offering.

  • On August 21, 2020, Planet 13 announced an upsize to bought deal public offering to CDN$20 million.

  • On September 10, 2020, Planet 13 announced closing of a CDN$23 million bought deal public offering.

  • On October 13, 2020, Planet 13 announced the addition of non-cannabis retail space to the Las Vegas SuperStore.

  • On October 19, 2020, Planet 13 announced expanding the dispensary floor of the Las Vegas SuperStore.

  • On October 19, 2020, Planet 13 announced a CDN$20 million bought deal public offering.

  • On October 20, 2020, Planet 13 announced an upsize to bought deal public offering to CDN$25 million.

  • On November 5, 2020, Planet 13 announced the closing of a CDN$28.8 million bought deal public offering.

  • On November 20, 2020, Planet 13 announced opening the Medizin dispensary.

Results of Operations (Summary)

The following tables set forth consolidated statements of financial information for the three-month and nine-month periods ending September 30, 2020 and September 30, 2019. For further information regarding the Company's financial results for these periods, please refer to the Company's interim financial statements for the period ended September 30, 2020 together with the MD&A, available on Planet 13's issuer profile on SEDAR at www.sedar.com and the Company's website https://www.planet13holdings.com.

Adjusted EBITDA

NV Cannabis Ops

Consolidated

Consolidated

NV Cannabis Ops

Consolidated

Three Months

Three Months

Three Months

Nine Months

Nine Months

Nine Months

Ended

Ended

Ended

Percentage

Ended

Ended

Ended

Percentage

Sep-30-2020

Sep-30-2020

Sep-30-2019

Change

Sep-30-2020

Sep-30-2020

Sep-30-2019

Change

EBITDA

Profit (loss) before taxes

4,811,541

3,371,829

251,122

1242.7

%

5,124,677

389,503

1,457,619

(73.3

%)

Add back:

Biological asset adjustments

504,069

504,069

52,291

864.0

%

225,294

225,294

129,101

74.5

%

Non-cash share based payments

-

569,227

2,016,803

(71.8

%)

-

2,006,067

3,128,417

(35.9

%)

Depreciation and amortization

1,076,774

1,076,774

680,056

58.3

%

3,103,847

3,103,847

1,945,186

59.6

%

Depreciation included in COGS

406,322

406,322

157,297

158.3

%

819,579

819,579

286,987

185.6

%

Interest and non-operating expense (income)

264,542

264,542

211,298

25.2

%

1,041,745

1,041,745

625,674

66.5

%

EBITDA

7,063,248

6,192,763

3,368,867

83.8

%

10,315,142

7,586,035

7,572,984

(0.2

%)

Margin

31.0

%

27.2

%

20.2

%

20.5

%

15.1

%

16.1

%

Expressed in USD$

Three Months

Three Months

Ended

Ended

Percentage

Sep-30-2020

Sep-30-2019

Change

Revenue

Revenues, net of discounts

22,797,338

16,696,932

36.5

%

Cost of Goods Sold

(9,821,561

)

(6,820,706

)

44.0

%

Gross Profit, Before Biological Asset Adjustment

12,975,777

9,876,226

31.4

%

Gross Profit Margin %

56.9

%

59.1

%

Realized fair value amounts included in COGS

(961,235

)

(562,461

)

70.9

%

Unrealized fair value gain on growth of biological assets

457,166

510,170

(10.4

%)

Gross profit

12,471,708

9,823,935

27.0

%

Gross Profit Margin %

54.7

%

58.8

%

Expenses

General and Administrative

6,198,121

4,902,355

26.4

%

Sales and Marketing

991,215

1,762,301

(43.8

%)

Depreciation and Amortization

1,076,774

680,056

58.3

%

Share based payments

569,227

2,016,803

(71.8

%)

Total Expenses

8,835,337

9,361,515

(5.6

%)

Income (Loss) From Operations

3,636,371

462,420

686.4

%

Other (Income) Expense:

Interest Expense, net

438,687

314,389

39.5

%

Realized Foreign Exchange gain (loss)

-

(6,203

)

(100.0

%)

Other expense (income)

(174,145

)

(96,888

)

79.7

%

Total Other Expense (Income)

264,542

211,298

25.2

%

Income (loss) for the period before tax

3,371,829

251,122

1242.7

%

Provision for income tax (current and deferred)

3,010,880

1,973,475

52.6

%

Income (Loss) for the period

360,949

(1,722,353)

(121.0

%)

Other Comprehensive Income (Loss)

Items that may be reclassified subsequently to profit/loss

Foreign exchange translation adjustment

(152,313

)

28,932

Net Comprehensive Income (Loss) for the period

208,636

(1,693,421)

Income (Loss) per share for the period

Basic and fully diluted loss per share

$

0.00

$

(0.01)

Weighted Average Number of Shares Outstanding

Basic and fully diluted

162,536,424

135,503,007

Outstanding Shares

As of November 24, 2020, the Company had 121,987,683 common shares and 55,232,940 class A convertible, restricted voting shares issued and outstanding for a total of 177,220,623 shares outstanding. There were 333,840 options issued and outstanding of which all have fully vested. There were 11,743,904 warrants outstanding and 1,764,250 RSU's outstanding of which nil RSUs had fully vested as at the date of this MD&A.

Conference Call

Planet 13 will host a conference call on Tuesday, November 24, 2020 at 5:00 p.m. EST to discuss its third quarter financial results and provide investors with key business highlights. The call will be chaired by Bob Groesbeck, Co-CEO, Larry Scheffler, Co-CEO, and Dennis Logan, CFO.

CONFERENCE CALL DETAILS

Date: November 24, 2020 | Time: 5:00 p.m. EST
Participant Dial-in: Toll Free 877-407-8035 or International 201-689-8035
Replay Dial-in: Toll Free 877-481-4010 or International 919-882-2331
(Available for 2 weeks)
Reference Number: 38726
Listen to webcast: https://bit.ly/358WpIA

Financial Measures

There are measures included in this news release that do not have a standardized meaning under generally accepted accounting principles (GAAP) and therefore may not be comparable to similarly titled measures and metrics presented by other publicly traded companies. The Company includes these measures because it believes certain investors use these measures and metrics as a means of assessing financial performance. EBITDA (earnings before interest, taxes, depreciation and amortization) is calculated as net earnings before finance costs (net of finance income), income tax expense, and depreciation and amortization of intangibles and is a non-GAAP financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies.

For further inquiries, please contact:

LodeRock Advisors Inc., Planet 13 Investor Relations
mark.kuindersma@loderockadvisors.com
(416) 519-2156 ext. 2230

Bob Groesbeck and Larry Scheffler
Co-Chief Executive Officers
ir@planet13lasvegas.com

About Planet 13

Planet 13 (www.planet13holdings.com) is a vertically integrated cannabis company based in Nevada, with award-winning cultivation, production and dispensary operations in Las Vegas - the entertainment capital of the world. Planet 13's mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. Planet 13's shares trade on the Canadian Stock Exchange (CSE) under the symbol PLTH and OTCQX under the symbol PLNHF.

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking-statements relate to, among other things, Planet 13's first California location and the timeline for opening of the Santa Ana dispensary.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: final regulatory and other approvals or consents; risks associated with COVID-19 and other infectious diseases presenting as major health issues; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Nevada and California cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the State of Nevada and California; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational and medicinal cannabis marketplace in the United States through licensed subsidiary entities in states that have legalized marijuana operations, however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company's business, including COVID-19, are contained under the heading "Risk Factors" and elsewhere in the Company's annual information form dated April 13, 2020 filed on its issuer profile on SEDAR at www.sedar.com.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Expressed in United States Dollars

As at

As at

September 30,

December 31,

2020

2019

Assets

Current Assets

Cash

$

56,760,860

$

12,814,712

HST receivable

63,860

16,544

Inventories (Note 5)

7,721,586

5,474,004

Biological assets (Note 6)

1,370,090

514,526

Prepaid expenses and other current assets (Note 10)

2,153,334

3,694,272

Total Current Assets

68,069,730

22,514,058

Property and equipment (Note 7)

31,638,285

30,211,154

Licenses (Note 8)

6,215,073

-

Right of use assets (Note 9)

18,520,944

9,478,733

Long-term deposits and other assets

1,031,352

694,601

57,405,654

40,384,488

Total Assets

$

125,475,384

$

62,898,546

Liabilities

Current Liabilities

Accounts payable (Note 16)

$

2,095,692

$

864,260

Accrued expenses

3,026,090

1,910,046

Income taxes payable

12,356,301

7,015,606

Notes payable - current portion (Note 11)

884,000

884,000

Total Current Liabilities

18,362,083

10,673,912

Long -term lease liabilities (Note 12)

20,437,005

10,522,377

Other long-term liabilities

28,000

28,000

Deferred tax liability

467,486

379,665

20,932,491

10,930,042

Total Liabilities

39,294,574

21,603,954

Shareholders' Equity

Share capital (Note 13)

101,809,657

51,986,849

Restricted share units (Note 13)

2,719,357

4,119,485

Warrants (Note 13)

7,753,818

5,961,091

Option reserve (Note 13)

311,401

399,439

Accumulated other comprehensive loss

(812,650

)

(607,707

)

Deficit

(25,600,773

)

(20,564,565

)

Total Shareholders' Equity

86,180,810

41,294,592

Total Liabilities and Shareholders' Equity

$

125,475,384

$

62,898,546

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND
COMPREHENSIVE
INCOME (LOSS)

Expressed in United States Dollars

Three months

Three months

Ended

Ended

September 30,

September 30,

2020

2019

Revenue

Revenues, net of discounts

$

22,797,338

$

16,696,932

Cost of Goods Sold

(9,821,561

)

(6,820,706

)

Gross Profit before fair value asset adjustment

12,975,777

9,876,226

Realized fair value amounts included in inventory sold

(961,235

)

(562,461

)

Unrealized fair value gain on growth of biological assets

457,166

510,170

Gross Profit

12,471,708

9,823,935

Expenses

General and Administrative (Note 14)

6,198,121

4,902,355

Sales and Marketing

991,215

1,762,301

Depreciation and Amortization (Note 7 & 9)

1,076,774

680,056

Share-Based Compensation Expense (Note 13 and Note 16)

569,227

2,016,803

Total Expenses

8,835,337

9,361,515

Income (Loss) From Operations

3,636,371

462,420

Other Expense:

Interest expense, net

438,687

314,389

Realized foreign exchange loss

-

(6,203

)

Other income

(174,145

)

(96,888

)

Total Other Expense

264,542

211,298

Income (Loss) before income taxes

3,371,829

251,122

Provision for tax - current

2,620,603

2,172,429

Provision for tax - deferred

390,277

(198,954

)

Income (Loss) for the Period

$

360,949

$

(1,722,353)

Other Comprehensive Income

Foreign exchange translation gain (loss)

(152,313

)

28,932

Net Comprehensive Income (Loss) for the Period

$

208,636

$

(1,693,421)

Income (Loss) per share for the Period

Basic and diluted Income (loss) per share

$

0.00

$

(0.01)

Weighted Average Number of Common Shares Outstanding

Basic and Diluted

162,536,424

135,503,007

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Expressed in United States Dollars

Nine Months

Nine Months

Ended

Ended

September 30,

September 30,

2020

2019

Operating activities

Net loss for the period

$

(5,036,208

)

$

(4,081,165

)

Add (deduct) non-cash items:

Share based payments (Note 13)

2,006,067

3,128,417

Depreciation and amortization (Note 7 & 9)

4,451,334

2,417,847

Deferred tax liability

87,821

(198,954

)

Deferred tax asset

-

-

Realized fair value amounts included in inventory sold

-

(759,856

)

Non-cash interest expense on ROU Liabilities (Note 12)

1,769,500

-

Net change in non-cash working capital

HST receivable

(47,316

)

77,473

Inventories (Note 5)

(2,247,582

)

422,949

Biological assets (Note 6)

(855,564

)

380,263

Prepaid expenses and other assets (Note 10)

1,540,938

(3,226,185

)

Long term deposits and other assets

(336,751

)

(85,000

)

Accounts payable

1,231,431

2,832,431

Accrued expenses

1,116,045

559,030

Income tax payable

5,340,695

5,737,738

Other liabilities

-

407,593

Cash flow provided by operating activities

9,020,410

7,612,581

Investing activities

Purchase of property, plant and equipment (Note 7)

(3,101,240

)

(12,682,554

)

Purchase of license (Note 8)

(1,053,353

)

-

Cash flow used in investing activities

(4,154,593)

(12,682,554)

Financing activities

Issuance of shares on warrant and option exercises (Note 13)

16,941,543

3,965,736

Issuance of shares and warrants on financings

23,807,651

-

Payment on lease liabilities

(1,463,920

)

(50,614

)

Cash flow provided by financing activities

39,285,274

3,915,122

Net increase in cash

44,151,091

(1,154,851)

Cash at beginning of the period

12,814,712

19,364,086

Effect of foreign exchange on cash

(204,943

)

(106,122

)

Cash at end of the period

$

56,760,860

$

18,103,113

SOURCE: Planet 13 Holdings Inc.



View source version on accesswire.com:
https://www.accesswire.com/618215/Planet-13-Announces-Record-Third-Quarter-2020-Financial-Results

Advertisement